
Photo: Depositphotos
Jul 11, 2025, 09:28
Akhil Santhosh: Long-Term Follow-Up of CM 577 in Esophageal Cancer
Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, shared a post on X:
“Long term follow up of CM 577 in Esophageal Cancer:
- Median OS 51.3m in adj nivolumab arm vs 35.3m in placebo
- only numerical improvement in OS (not statistically sig).
Benefit more for PDL1>1 and squamous subset, end of the road for CROSS and CM 577?”
More posts featuring Akhil Santhosh on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 11, 2025, 09:28
Jul 11, 2025, 09:15
Jul 11, 2025, 09:14
Jul 11, 2025, 09:07
Jul 11, 2025, 08:59
Jul 11, 2025, 08:19
Jul 11, 2025, 07:44
Jul 11, 2025, 07:19